[1] 薛小燕,郭小华,李敏,等. 神经退行性疾病发病机制研究进展[J]. 中国老年学杂志, 2015, 35(11): 3149-3152.
[2] 张宁,李韶菁,余红,等. 神经血管单元信号通路机制研究进展[J]. 中国新药杂志, 2012, 21(14): 1621-1626.
[3] Sá-Pereira I, Brites D, Brito MA.Neurovascular unit: a focus on pericytes[J]. Mol Neurobiol, 2012, 45(2): 327-347.
[4] Winkler EA, Bell RD, Zlokovic BV.Central nervous system pericytes in health and disease[J]. Nat Neurosci, 2011, 14(11): 1398-1405.
[5] 许兵,张俞,杜久林. 血脑屏障的研究进展[J]. 生理学报, 2016, 68(3): 306-322.
[6] Fricker G.Drug transport across the blood-brain barrier[J]. Pharm Weekbl Sci, 1992, 14(5): 305-310.
[7] Farrington GK, Caram-Salas N, Haqqani AS, et al.A novel platform for engineering blood-brain barrier-crossing bispecific biologics[J]. FASEB J, 2014, 28(11): 4764-4778.
[8] Prades R, Ollersalvia B, Schwarzmaier SM, et al.Applying the retro-enantio approach to obtain a peptide capable of overcoming the blood-brain barrier[J]. Angew Chem Int Ed Engl, 2015, 54(13): 3967-3972.
[9] Lajoie JM, Shusta EV.Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier[J]. Annu Rev Pharmacol Toxicol, 2015, 55(1): 613-631.
[10] Parrish KE, Sarkaria JN, Elmquist WF.Improving drug delivery to primary and metastatic brain tumors: Strategies to overcome the blood-brain barrier[J]. Clin Pharmacol Ther, 2015, 97(4): 336-346.
[11] Hawkins BT, Davis TP.The blood-brain barrier/neurovascular unit in health and disease[J]. Pharmacol Rev, 2005, 57(2): 173-185.
[12] Hamel E.Perivascular nerves and the regulation of cerebrovascular tone[J]. J Appl Physiol (1985), 2006, 100(3): 1059-1064.
[13] 唐强,葛腾,朱路文. 脑缺血后神经血管单元保护的研究进展[J]. 中国康复医学杂志, 2014, 29(10): 991-994.
[14] Benarroch EE.Neurovascular unit dysfunction: a vascular component of Alzheimer disease?[J]. Neurology, 2008, 70(3): 243-244.
[15] Xing C, Hayakawa K, Lok J, et al.Injury and repair in the neurovascular unit[J]. Neurol Res, 2012, 34(4): 325-330.
[16] Zlokovic BV.The blood-brain barrier in health and chronic neurodegenerative disorders[J]. Neuron, 2008, 57(2): 178-201.
[17] 齐志刚,李坤成,王军. 为更早识别阿尔茨海默病:阿尔茨海默病神经影像学计划简介[J]. 中国现代神经疾病杂志, 2014, 14(4): 277-280.
[18] 张贺奡,庆宏. 阿尔茨海默症发病机制及治疗方法研究进展[J]. 科技导报, 2017, 35(10): 52-63.
[19] 胡谦锋,周春祥,于蓓蓓. 中药调控血脑屏障对Aβ的转运[J]. 世界科学技术-中医药现代化, 2015, 17(9): 1906-1910.
[20] Grammas P.Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease[J]. J Neuroinflammation, 2011, 8: 26.
[21] Altman R, Rutledge JC.The vascular contribution to Alzheimer's disease[J]. Clin Sci (Lond), 2010, 119(10): 407-421.
[22] Bowman GL, Kaye JA, Moore M, et al.Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance[J]. Neurology, 2007, 68(21): 1809-1814.
[23] Bell RD, Zlokovic BV.Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease[J]. Acta Neuropathol, 2009, 118(1): 103-113.
[24] Bruijn LI, Miller TM, Cleveland DW.Unraveling the mechanisms involved in motor neuron degeneration in ALS[J]. Annu Rev Neurosci, 2004, 27: 723-749.
[25] Garbuzova-Davis S, Haller E, Saporta S, et al.Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS[J]. Brain Res, 2007, 1157(1): 126-137.
[26] Garbuzovadavis S, Saporta S, Sanberg PR.Implications of blood-brain barrier disruption in ALS[J]. Amyotroph Lateral Scler, 2008, 9(6): 375-376.
[27] Zhong Z, Deane R, Ali Z, et al.ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration[J]. Nat Neurosci, 2008, 11(4): 420-422.
[28] Garbuzova-Davis S, Rodrigues MCO, Hernandez-Ontiveros DG, et al.Amyotrophic lateral sclerosis: A neurovascular disease[J]. Brain Res, 2011, 1398(5): 113-125.
[29] Vangilder RL, Rosen CL, Barr TL, et al.Targeting the neurovascular unit for treatment of neurological disorders[J]. Pharmacol Ther, 2011, 130(3): 239-247.
[30] 王卫娇,田丹珂. 王宝亮教授治疗亨廷顿舞蹈病1例[J]. 中医研究, 2016, 29(6): 43-44.
[31] Drouin-Ouellet J, Sawiak SJ, Cisbani G, et al.Cerebrovascular and blood-brain barrier impairments in Huntington's disease: potential implications for its pathophysiology[J]. Ann Neurol, 2015, 78(2): 160-177.
[32] Zlokovic BV.Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders[J]. Nat Rev Neurosci, 2011, 12(12): 723-738.
[33] Stamour I, Aubé B, Rieux M, et al.Targeting cerebrovascular impairments in Huntington's disease: a novel treatment perspective[J]. Neurodegener Dis Manag, 2015, 5(5): 389-393.
[34] Huang WJ, Chen WW, Zhang X.Multiple sclerosis: pathology, diagnosis and treatments[J]. Exp Ther Med, 2017, 13(6): 3163-3166.
[35] 彭真,张礼标,吴洁,等. 多发性硬化动物模型研究进展[J]. 动物医学进展, 2017, 38(4): 108-112.
[36] Naegele M, Martin R.The good and the bad of neuroinflammation in multiple sclerosis[J]. Handb Clin Neurol, 2014, 122(3): 59-87.
[37] 王启荣,卢祖能,毛春,等. T细胞亚群与多发性硬化发病机制的关系[J]. 医学综述, 2017, 23(15): 2918-2922.
